Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK102 Long-term Treatment in Hypercholesterolemia (Extension of AK102-201/202/203)
CTR20191937Phase 2Completed
- Sponsor
- Kangrong Dongfang
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ebronucimab in hypercholesterolemia, sponsored by Kangrong Dongfang. Started Oct 2019; status: completed.
02
Drugs
ebronucimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20191937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191937.